Co-Authors
This is a "connection" page, showing publications co-authored by Mark Mulligan and Kristin Tompkins.
Connection Strength
0.513
-
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2021 Feb; 590(7844):E26.
Score: 0.232
-
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 10; 586(7830):589-593.
Score: 0.224
-
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 12 17; 383(25):2439-2450.
Score: 0.057